| Literature DB >> 30086666 |
Hsiu-Yin Chiang1,2, Tung-Han Wu3, Chiann-Yi Hsu1, Wen-Cheng Chao1,4,5.
Abstract
The number of patients with cancer being admitted to intensive care units (ICUs) is increasing worldwide, and these patients are vulnerable to infection. This study aimed to address the long-term impact of positive cultures during admission on 1-year mortality among patients with cancer who received perioperative intensive care. This retrospective cohort study enrolled adult patients with cancer who were admitted to ICUs and received surgery during 2011 to 2016 at a tertiary hospital in central Taiwan. Cancer-related data were retrieved from the cancer registry, and data during ICU admissions were obtained from the electronic medical records. We compared the survival curves between patients with and without positive clinical cultures using log-rank test and used a multivariable Cox proportional hazards regression model to evaluate the influence of positive clinical cultures on 1-year mortality. A total of 638 patients were included for analyses, and 37.9% of them had positive cultures during the index admission. In-hospital mortality was 9.1%, while 1-year mortality was 21.0%. Compared with patients who survived, patients who died were significantly more likely to have positive cultures (59.7% vs 32.1%), to have a higher Acute Physiology and Chronic Health Evaluation II scores (median 21.8 vs 19.0), and to receive mechanical ventilation (86.6% vs 77.4%). Survival analysis found that positive cultures of blood, the respiratory tract, the urinary tract, or the skin and soft tissue were associated with an increased 1-year mortality. Multivariable Cox proportional hazards regression analysis found that positive cultures of blood, the respiratory tract, the urinary tract, or the skin and soft tissue (hazard ratio: 1.621; 95% confidence interval: 1.087-2.419) were significantly associated with 62.1% increased hazards of death within 1 year after the ICU admission. A positive culture during admission was associated with a worsened long-term survival among patients with cancer who received perioperative intensive care. Further studies are needed to confirm this association.Entities:
Keywords: critical illness; neoplasms/mortality; perioperative medicine; registries; survival analysis
Mesh:
Substances:
Year: 2018 PMID: 30086666 PMCID: PMC6083771 DOI: 10.1177/1073274818794162
Source DB: PubMed Journal: Cancer Control ISSN: 1073-2748 Impact factor: 3.302
Figure 1.Selection process of the study population.
Characteristics of the 638 Patients With Cancer Receiving a Surgery With ICU Admission Categorized by 1-Year Survival.
| Alla (N = 638) | Survivora (n = 504) | Nonsurvivora (n = 134) |
| |
|---|---|---|---|---|
| Basic characteristics | ||||
| Age at index ICU admission (years) | 60.4 (52.1-71.8) | 58.8 (49.9-68.8) | 66.3 (56.5-76.2) | <.01 |
| Male | 493 (77.3%) | 384 (76.2%) | 109 (81.3%) | .25 |
| Emergent surgery | 115 (18.0%) | 67 (13.3%) | 48 (35.8%) | <.01 |
| Type II diabetes mellitus | 138 (21.6%) | 101 (20%) | 37 (27.6%) | .08 |
| Chronic obstructive pulmonary disease | 102 (16%) | 77 (15.3%) | 25 (18.7%) | .35 |
| Cerebrovascular disease | 93 (14.6%) | 64 (12.7%) | 29 (21.6%) | .01 |
| Congestive heart failure | 32 (5.0%) | 17 (3.4%) | 15 (11.2%) | <.01 |
| Chronic renal disease | 16 (2.5%) | 11 (2.2%) | 5 (3.7%) | .35 |
| Types of cancer | ||||
| Gastroesophageal cancer | 181 (28.4%) | 146 (29%) | 35 (26.1%) | .52 |
| Head neck cancer | 125 (19.6%) | 107 (21.2%) | 18 (13.4%) | .43 |
| Brain cancer | 93 (14.6%) | 85 (16.9%) | 8 (6%) | .02 |
| Colon cancer | 75 (11.8%) | 50 (9.9%) | 25 (18.7%) | .05 |
| Lung cancer | 51 (8.0%) | 35 (6.9%) | 16 (11.9%) | .06 |
| Hepatocellular carcinoma | 22 (3.4%) | 16 (3.2%) | 6 (4.5%) | .46 |
| Prostate cancer | 16 (2.5%) | 11 (2.2%) | 5 (3.7%) | .30 |
| Hematological malignancy | 10 (1.6%) | 5 (1.0%) | 5 (3.7%) | .02 |
| Others | 65 (10.2%) | 49 (9.7%) | 16 (11.9%) | .45 |
| Cancer status and treatment | ||||
| Presence of metastasis | 350 (54.9%) | 252 (50.0%) | 98 (73.1%) | <.01 |
| Surgery | 538 (87.1%) | 446 (91.6%) | 92 (70.2%) | <.01 |
| Chemotherapy | 358 (62.5%) | 282 (62.9%) | 76 (60.8%) | .68 |
| Radiotherapy | 295 (46.2%) | 246 (48.8%) | 49 (36.6%) | .15 |
| Hormone therapy | 86 (7.2%) | 52 (6.9%) | 34 (7.7%) | .58 |
| Target therapy | 138 (11.5%) | 69 (9.1%) | 69 (15.7%) | <.01 |
| Microbiologic data | ||||
| Positive clinical culturesc | 242 (37.9%) | 162 (32.1%) | 80 (59.7%) | <.01 |
| Positive MDROd | 49 (7.7%) | 25 (5.0%) | 24 (17.9%) | <.01 |
| Management and outcome | ||||
| APACHE II score | 20.0 (14.0-22.0) | 19.0 (14.0-21.8) | 21.8 (17.0-25.0) | <.01 |
| Mechanical ventilation | 506 (79.3%) | 390 (77.4%) | 116 (86.6%) | .02 |
| Renal replacement therapy | 4 (0.6%) | 2 (0.4%) | 2 (1.5%) | .42 |
| ICU stay (days) | 5 (4-8) | 5 (4-8) | 6 (6-13) | <.01 |
| Hospital stay (days) | 15 (11-23) | 14 (10-22) | 20 (12.8-35.0) | <.01 |
| In-hospital mortality | 58 (9.1%) | 0 (0%) | 58 (43.3%) | <.001 |
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; MDRO, multidrug resistant organisms.
a Data are presented as median (interquartile range) for continuous variables and number (percentage) for categorical variables.
b We compared the difference between survivors and nonsurvivors using Wilcoxon rank sum test (continuous variables) or χ2 test (categorical variables).
c Cultures were obtained from blood, respiratory tract, urinary tract, skin and soft tissue, or abdomen during the index admission.
d MDRO included methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and carbapenem-resistant Gram-negative bacilli.
Pathogens Identified in the Cultures of 242 Patients With Cancer During Their Index Admission.
| Total (N = 242), n (%) | Blood (n = 36), n (%) | Respiratory Tract (n = 153), n (%) | Urinary Tract (n = 56), n (%) | Skin and Soft Tissue (n = 114), n (%) | Abdomen (n = 33), n (%) | |
|---|---|---|---|---|---|---|
| Gram-positive cocci | 50 (20.7%) | 7 (19.4%) | 8 (5.2%) | 5 (8.9%) | 31 (27.2%) | 8 (24.2%) |
|
| 18 (7.4%) | 5 (13.9%) | 8 (5.2%) | 0 (0%) | 7 (6.1%) | 0 (0%) |
| Methicillin-resistant | 15 (6.2%) | 5 (13.9%) | 5 (3.3%) | 0 (0%) | 7 (6.1%) | 0 (0%) |
| | 33 (13.6%) | 2 (5.6%) | 0 (0%) | 5 (8.9%) | 24 (21.1%) | 8 (24.2%) |
| Vancomycin-resistant | 1 (0.4%) | 1 (2.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| GNB | 224 (92.6%) | 25 (69.4%) | 147 (96.1%) | 37 (66.1%) | 101 (88.6%) | 24 (72.7%) |
|
| 119 (49.2%) | 4 (11.1%) | 86 (56.2%) | 12 (21.4%) | 54 (47.4%) | 7 (21.2%) |
|
| 89 (36.8%) | 7 (19.4%) | 48 (31.4%) | 8 (14.3%) | 32 (28.1%) | 7 (21.2%) |
|
| 55 (22.7%) | 6 (16.7%) | 8 (5.2%) | 14 (25%) | 28 (24.6%) | 13 (39.4%) |
|
| 51 (21.1%) | 4 (11.1%) | 78 (51%) | 4 (7.1%) | 20 (17.5%) | 2 (6.1%) |
| Other GNB | 70 (28.9%) | 11 (30.6%) | 19 (12.4%) | 13 (23.2%) | 33 (28.9%) | 5 (15.2%) |
| Carbapenem-resistant GNB | 40 (16.5%) | 3 (8.3%) | 23 (15%) | 6 (10.7%) | 20 (17.5%) | 3 (9.1%) |
|
| 56 (23.1%) | 11 (30.6%) | 4 (2.6%) | 25 (44.6%) | 21 (18.4%) | 12 (36.4%) |
|
| 38 (15.7%) | 6 (16.7%) | 3 (2%) | 14 (25%) | 20 (17.5%) | 8 (24.2%) |
|
| 7 (2.9%) | 2 (5.6%) | 3 (2%) | 5 (8.9%) | 0 (0%) | 0 (0%) |
|
| 2 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (6.1%) |
|
| 10 (4.1%) | 2 (5.6%) | 1 (0.7%) | 6 (10.7%) | 2 (1.8%) | 3 (9.1%) |
| Yeast | 11 (4.5%) | 4 (11.1%) | 0 (0%) | 9 (16.1%) | 1 (0.9%) | 1 (3%) |
Abbreviation: GNB, gram-negative bacilli.
Figure 2.Kaplan-Meier survival curves for patients with and without positive cultures categorized by culture sites. All culture sites (A), blood (B), respiratory tract (C), urinary tract (D), skin or soft tissue (E), abdomen (F).
Cox Proportional Hazards Regression for 1-Year Mortality.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Age, per 1 year increment | 1.037 (1.024-1.050) | <.01 | 1.017 (1.001-1.032) | .03 |
| Male gender | 1.240 (0.803-1.915) | .33 | 1.622 (1.038-2.535) | .03 |
| Type II diabetes mellitus | 1.446 (0.990-2.111) | .06 | 1.214 (0.822-1.793) | .33 |
| Cerebrovascular disease | 1.780 (1.179-2.685) | <.01 | 1.065 (0.678-1.675) | .78 |
| Congestive heart failure | 2.875 (1.679-4.925) | <.01 | 2.074 (1.161-3.704) | .01 |
| Metastatic cancer | 2.434 (1.661-3.567 | <.01 | 2.293 (1.552-3.387) | <.01 |
| Emergent surgery | 3.921 (2.744-5.602) | <.01 | 1.992 (1.305-3.041) | <.01 |
| APACHE II, per 1 increment | 1.079 (1.050-1.108) | <.01 | 1.047 (1.015-1.079) | <.01 |
| Mechanical ventilation | 1.755 (1.068-2.884) | .03 | 1.128 (0.668-1.905) | .65 |
| Positive culture of MDRO | 3.282 (2.451-5.979) | <.01 | 1.407 (0.846-2.338) | .19 |
| Positive culture in blood/respiratory tract/urinary tract/skin and soft tissue | 2.869 (2.035-4.046) | <.01 | 1.621 (1.087-2.419) | .03 |
Abbreviations: APACHE, acute physiology and chronic health evaluation; CI, confidence interval; HR, hazard ratio; MDRO, multidrug resistant organisms.
Figure 3.Kaplan-Meier survival curves for patients with and without 1 of the 3 major pathogens. Gram-positive cocci (A), gram-negative bacilli (B), and candida/yeast (C).